MMI :: Robotic Surgery Technologies Designed Specifically for the Micro Level

MMI is a specialized robotics company focused on advancing precision in open soft-tissue microsurgery and supermicrosurgery. Founded in 2015 near Pisa, Italy, by engineers with deep expertise in surgical robotics, the company has grown into a global leader in robotic technologies designed specifically for the micro level. Its headquarters are now based in the United States while maintaining significant innovation and manufacturing operations in Italy.

The centerpiece of MMI’s portfolio is the Symani® Surgical System, the only commercially available robotic platform purpose-built for microsurgery and supermicrosurgery. The system delivers unmatched precision through a combination of the world’s smallest wristed instruments (NanoWrist®), tremor reduction, and motion scaling of up to 20x. This allows surgeons to translate natural, larger hand movements into tiny, highly controlled actions at the scale of blood vessels, lymphatic ducts, and nerves between 0.1 mm and 2.5 mm.

MMI’s robotic instruments include standard and supermicro versions, with the newer NanoWrist dissection tools (scissors and forceps) expanding capabilities beyond anastomosis to include delicate tissue dissection and manipulation. These instruments provide seven degrees of freedom while replicating natural hand movements at a microscopic level. The system also integrates with the company’s SynaptiX digital surgery platform, which adds visual enhancements, streamlined workflows, and data-driven tools directly for open microsurgical procedures.

Clinical applications for Symani span reconstructive surgery, including lymphatic repair for lymphedema, autologous breast reconstruction, head and neck cancer reconstruction, and trauma repair. Studies and real-world use have shown benefits such as 100% anastomosis patency rates on very small vessels (compared with roughly 80% manually), substantial reductions in flap loss, and meaningful decreases in limb volume for lymphedema patients. The platform is being tested in new areas, including a first-in-human neurosurgical trial and the REMIND study exploring robotic microsurgery for Alzheimer’s patients by targeting lymphatic drainage around the brain.

MMI received FDA De Novo authorization in the United States (making Symani the only robotic system cleared there for reconstructive microsurgery at this scale), CE marking in Europe, and approvals in more than 35 countries. The company has raised over $225million,includinga$110 million Series C round led by Fidelity in 2024. With roughly 250–280 employees across the U.S., Europe, and Asia, MMI continues to expand commercial adoption while developing broader capabilities for the robotic microsurgery platform.